Mesenchymal stem cells are the origin for osteoblasts, but MSC transplantation has not resulted in long-term success as a treatment option for brittle bone disease. Hematopoietic stem cells usually give rise to blood cells and osteoclasts, but researchers hypothesized that they could give rise to osteoblasts too. By replacing osteoblasts, they offer a potential therapeutic opportunity that is not dependent on a specific mutation but simply on a mutation being present, which gives patients hope.
